Clinical Trials Logo

Dwarfism, Pituitary clinical trials

View clinical trials related to Dwarfism, Pituitary.

Filter by:

NCT ID: NCT00136032 Completed - Clinical trials for Growth Hormone Deficiency

Growth Hormone Administration and Its Effects on Cardiovascular Risk Factors in Growth Hormone Deficient Women

Start date: January 2002
Phase: N/A
Study type: Interventional

The purpose of the study is to evaluate the effects of growth hormone replacement on women with growth hormone deficiency. Growth hormone deficiency means the body no longer produces growth hormone due to a tumor or some kind of disease of the brain in an area called the pituitary/hypothalamic region. This is the area of the brain where growth hormone is normally produced. We, the researchers at Massachusetts General Hospital, will establish the effects of growth hormone replacement on cardiovascular parameters (laboratory tests, the flexibility of the arteries, changes in heart rate) in women with growth hormone deficiency. Our goal is to see if this therapy: - has effects on women's cardiovascular risk markers (special blood tests which indicate how healthy the heart and arteries are) - has effects on women's types and levels of various substances circulating in their blood - in women affects the stiffness of their arteries and heart rate variability in parallel with changes in cardiovascular risk markers - has different effects depending on whether women are pre or post menopausal. Participation in this study is expected to last approximately 12 months.

NCT ID: NCT00134420 Completed - Clinical trials for Growth Hormone Deficiency

Growth Hormone and Chromosome 18q- and Abnormal Growth

Start date: February 2001
Phase: Phase 3
Study type: Interventional

We, the investigators at the University of Texas Health Science Center at San Antonio, want to learn if height and IQ (intelligence quotient) scores are improved by growth hormone (GH) treatment in children with chromosome 18 deletions and abnormal growth. Data from a previous study showed that growth hormone improved height in all children with 18q- and growth hormone deficiency. In addition, most of the study participants on growth hormone treatment showed an increase in IQ scores.

NCT ID: NCT00109733 Completed - Pituitary Dwarfism Clinical Trials

Cool.Click™ Adolescent Transition Study: Study of Saizen® in Subjects With Childhood-onset Growth Hormone Deficiency

Start date: January 2005
Phase: Phase 3
Study type: Interventional

The primary objective is to evaluate the efficacy and safety of two different dose regimens of r-hGH (Saizen®) in subjects with childhood-onset growth hormone deficiency (COGHD) during the transition phase from childhood to adulthood.

NCT ID: NCT00102817 Completed - Clinical trials for Growth Hormone Disorder

Somatropin (Norditropin) in Insulin-like Growth Factor (IGF) Deficient Children

Start date: May 2003
Phase: Phase 3
Study type: Interventional

This trial is conducted in the United States of America (USA). This is a 12 month study to determine if Norditropin is safe and effective in children with IGF deficiency.

NCT ID: NCT00102258 Completed - Short Stature Clinical Trials

Role of Nutrition and Hormones in Boys With Disordered Growth

Start date: January 19, 2005
Phase: Phase 2
Study type: Interventional

This study will determine whether adding more calories to the diet helps boys with growth problems grow better while being treated with Nutropin, a growth hormone that is used to help children grow taller. The Food and Drug Administration has approved Nutropin for use in children who are very short. This study will examine whether giving nutritional supplements in addition to Nutropin can help children grow better than with Nutropin alone. Boys between 7 and 10 years of age who are very short and below average in weight, but are otherwise healthy may be eligible for this study. Candidates must qualify for Nutropin treatments to boost their growth. Boys will be recruited for the study from the Nemours Children's Clinic in Jacksonville, FL, and from the National Institutes of Health in Bethesda, MD. Participants are randomly assigned to one of two treatment groups. One group is observed for 6 months and then receives a Nutropin injection every day for 12 months. The second group drinks 8 ounces of a high-calorie beverage called Pediasure every day for 6 months and then receives Nutropin plus Pediasure every day for 12 months. In addition to treatment, participants undergo the following tests and procedures at the schedule indicated: Baseline, 3, 6, 9, 12, 15 and 18 months - Clinical examination - Height measurement - Body composition assessment: Skin-fold thickness calipers are used in four places on the body to estimate body fat - Bioelectric impedance: A small amount of electrical current is used to calculate the percentage of body fat. Baseline, 6, 12, and 18 months - Blood tests - Bone age x-ray: x-ray of the left hand to measure growth potential - DEXA (dual energy x-ray absorptiometry) scan: x-ray scan to measure body fat, muscle, and bone mineral content. The subject lies on a flat table during the scan. Baseline, 6, and 12 months - Record of dietary intake: Parents are asked to write down everything the child eats and drinks for 3 days. Using this record, a dietitian calculates the daily caloric intake. - Total energy expenditure: This test determines how much energy the child uses. For the test, the child drinks water labeled with harmless isotopes (heavy oxygen and heavy hydrogen). For the next 10 days he collects urine in plastic tubes at home. At the end of the 10 days, the parents bring the urine to the clinic for analysis to determine how fast the labeled water leaves the body. This information is used to calculate how much energy the child expends each day. Participants' weight is measured at 2 and 4 weeks, and then monthly for the remainder of the 18-month study.

NCT ID: NCT00097526 Completed - Turner Syndrome Clinical Trials

Bone Mineral Density (BMD) in Adolescents With Growth Hormone Deficiency (GHD)

Start date: April 2000
Phase: Phase 4
Study type: Observational

This study is a multicenter, open-label, postmarketing surveillance study. The substudy will collect information on BMD in adolescents and young adults with GHD or Turner syndrome who are completing GH treatment for statural indications.

NCT ID: NCT00097513 Completed - Dwarfism, Pituitary Clinical Trials

National Cooperative Growth Study (NCGS) of Optimal Nutropin AQ and Nutropin Dosing in Pubertal Growth Hormone-Deficient (GHD) Patients

Start date: February 2003
Phase: Phase 4
Study type: Observational

This study is a multicenter, open-label, observational, postmarketing surveillance study that will collect information on the use of Genentech GH preparations to treat GH-deficient subjects with optimal GH dosing during puberty.

NCT ID: NCT00080483 Completed - Hypogonadism Clinical Trials

Testosterone and Growth Hormone for Bone Loss in Men

Start date: March 2004
Phase: Phase 2
Study type: Interventional

Deficiency of testosterone, growth hormone, or both hormones can result in osteoporosis. If either hormone is replaced, the condition of the bones improves. The purpose of this study is to determine if dual hormone treatment for men deficient in testosterone and growth hormone improves bone structure more than testosterone treatment alone.

NCT ID: NCT00006394 Completed - Osteoporosis Clinical Trials

Randomized Study of Growth Hormone on Bone Mineral Density in Patients With Adult Onset Growth Hormone Deficiency

Start date: April 1997
Phase: N/A
Study type: Interventional

OBJECTIVES: I. Compare whether the bone tissue in the spine and hip improves in patients with adult onset growth hormone deficiency treated with growth hormone (GH) vs placebo. II. Determine whether the blood samples of these patients show evidence of beneficial bone effects after treatment with GH. III. Compare the quality of life of these patients treated with these 2 regimens. IV. Determine the side effects of GH in these patients.

NCT ID: NCT00004365 Completed - Clinical trials for Growth Hormone Deficiency

Study of Pituitary Size and Function in Familial Dwarfism of Sindh

Start date: September 1995
Phase: N/A
Study type: Observational

OBJECTIVES: I. Assess pituitary size and anatomic configuration by magnetic resonance imaging (MRI) in 4 affected dwarfs in the province of Sindh, Pakistan. II. Evaluate ultradian growth hormone (GH) secretory patterns in 4 affected dwarfs.